EDSA Edesa Biotech, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1540159 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-138.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-122.9%
ROA-102.5%
ROIC (approx.)-9,500.4%
Asset turnover—
Leverage & solvency
Liabilities / assets30.7%
Debt / equity0.00x
Current ratio2.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-37.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-06-30 | 2026Q22026-03-31 | 2026Q12025-12-31 | 2025Q4*2025-09-30 | 2025Q32025-06-30 | 2025Q22025-03-31 | 2025Q12024-12-31 | 2024Q4*2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $3.96M | $2.77M | $1.12M | $1.23M | $939,067 | $484,306 | $1.02M | $103,867 |
| SG&A expense | $1.56M | $1.53M | $1.22M | $1.24M | $964,676 | $1.15M | $878,871 | $900,529 |
| Operating income | -$5.52M | -$4.30M | -$2.34M | -$2.47M | -$1.90M | -$1.64M | -$1.90M | -$1.00M |
| Pretax income | -$5.41M | -$4.22M | — | -$2.23M | -$1.75M | -$1.59M | — | -$962,051 |
| Income tax | $0 | $800 | — | $0 | $0 | $800 | — | $0 |
| Net income | -$5.41M | -$4.22M | -$2.25M | -$2.23M | -$1.75M | -$1.59M | -$1.62M | -$962,051 |
| EBITDA | -$5.49M | -$4.27M | -$2.32M | -$2.44M | -$1.88M | -$1.61M | -$1.86M | -$960,190 |
| EPS (basic) | -0.60 | -0.49 | -0.28 | — | -0.25 | -0.30 | -0.48 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $10.30M | $10.00M | $12.10M | $10.79M | $12.40M | $13.90M | $1.60M | $1.04M |
| Current assets | $10.78M | $10.42M | $12.72M | $11.51M | $12.76M | $14.39M | $2.07M | $1.68M |
| PP&E, net | — | — | — | — | — | — | — | $0 |
| Intangibles | $1.90M | $1.93M | $1.95M | $1.98M | $2.00M | $2.03M | $2.05M | $2.08M |
| Total assets | $12.72M | $12.38M | $14.71M | $13.53M | $14.80M | $16.45M | $4.16M | $3.81M |
| Current liabilities | $3.91M | $2.19M | $756,163 | $1.08M | $672,674 | $914,701 | $1.90M | $1.83M |
| Total liabilities | $3.91M | $2.19M | $756,163 | $1.08M | $672,674 | $914,701 | $1.90M | $1.83M |
| Shareholders' equity | $8.81M | $10.20M | $13.95M | $12.45M | $14.13M | $15.54M | $2.26M | $1.98M |
| Shares outstanding | 9.63M | 8.89M | 8.33M | 7.14M | 7.02M | 7.02M | 3.47M | 3.25M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.08M | -$2.02M | -$2.09M | -$1.72M | -$1.70M | -$2.38M | -$1.52M | -$967,039 |
| Financing cash flow | $3.45M | -$8,980 | $3.36M | $186,483 | $0 | $14.77M | $2.07M | -$31,435 |
| Depreciation & amortization | $25,644 | $25,872 | $25,460 | $25,868 | $25,787 | $24,509 | $43,109 | $44,206 |
| Stock-based compensation | $500,000 | $480,000 | $399,862 | $404,425 | $200,000 | $70,000 | $81,183 | $93,933 |
Free plan shows the latest 8 periods; Pro shows all 50 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.